Author(s):
Statin usage has been shown to reduce the incidence and increase survival of gynecologic malignancies, although its effect on endometrial carcinoma (EC) is still unclear. Our main goal is to look at statin usage and its correlation with early-stage EC characteristics associated with high intermediate risk (HIR). Our hypothesis is that statin-taking women who have early-stage EC have less aggressive pathology at the time of hysterectomy. Our secondary goal is to find out whether using bisphosphonates, NSAIDs, and metformin concurrently may lower the chance of developing HIR early stage EC. These drugs all have anti-cancer properties.
